Related Experiment Video

Updated: Jul 14, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Octreotide and hepatocellular carcinoma

F Farinati, A Sergio, A Baldan

    British Journal of Cancer
    |May 17, 2007
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
    06:38

    An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

    Published on: September 12, 2019

    Related Experiment Videos

    Last Updated: Jul 14, 2026

    Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
    09:11

    Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

    Published on: May 24, 2024

    An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
    06:38

    An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

    Published on: September 12, 2019

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

    Articles linked to this work by shared authors, journal, and citation graph.

    A multicenter real-world, open-label study assessing the impact of a probiotic mixture on symptoms of irritable bowel syndrome in adults.

    Beneficial microbes·2025

    Duration of efficacy and effect of implant location in adult queens treated with a 9.4 mg deslorelin subcutaneous implant.

    Theriogenology·2024

    Calcitonin levels in autoimmune atrophic gastritis-related hypergastrinemia.

    Journal of endocrinological investigation·2023

    Diagnostic Accuracy of EndoFaster® and Narrow-Band Imaging Endoscopy in Patients with Impaired Gastric Acid Secretion: A Real-Time Prospective Study.

    Gastroenterology research and practice·2021

    T2-weighted, apparent diffusion coefficient and <sup>18</sup>F-FDG PET histogram analysis of rectal cancer after preoperative chemoradiotherapy.

    Techniques in coloproctology·2021

    Macrophage secretion of miR-106b-5p causes renin-dependent hypertension.

    Nature communications·2020

    Combining genome-wide polygenic scores with registry data for colorectal cancer risk-based screening.

    British journal of cancer·2026

    Reactivation of DRP1 plays a functional role in resistance to MEK inhibition in pancreatic cancer cells.

    British journal of cancer·2026

    Targeting Siglec-engaging immunosuppressive sialoglycans to suppress prostate cancer bone metastasis.

    British journal of cancer·2026

    Anthropometric traits, metabolic biomarkers, and pancreatic cancer risk: a causal mediation analysis in UK Biobank.

    British journal of cancer·2026

    TP53 mutation-biased CD8<sup>+</sup> T cell exhaustion drives lethal outcome and therapy resistance in urothelial carcinoma.

    British journal of cancer·2026

    Paediatric therapeutic development workshop on medulloblastoma.

    British journal of cancer·2026

    Clinical characteristics, surgical management, and outcomes of uterine smooth muscle tumours of uncertain malignant potential: a single-centre experience.

    Przeglad menopauzalny = Menopause review·2026

    BCR-ABL1 Transcript Variants in Chronic Myeloid Leukemia Patients in Africa: A Systematic Review.

    Health science reports·2026

    Classical Hodgkin Lymphoma Today.

    Mediterranean journal of hematology and infectious diseases·2026

    Jiedu Xiaoliu formula enhances progression-free survival and immune modulation in diffuse large B-cell lymphoma: a retrospective cohort study.

    Frontiers in pharmacology·2026

    LTF promotes central nervous system leukemia progression via neutrophil serine proteases.

    Frontiers in pharmacology·2026

    Case Report: refractory hemophagocytic lymphohistiocytosis progression despite complete metabolic response in a patient with stage IV extranodal NK/T-cell lymphoma: clinical observation of "tumor-immune dissociation" phenomenon.

    Frontiers in immunology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us